Deimos Asset Management LLC purchased a new position in Eli Lilly and Co. (NYSE:LLY) during the second quarter, according to its most recent filing with the SEC. The fund purchased 12,000 shares of the company’s stock, valued at approximately $945,000.

Several other large investors have also recently made changes to their positions in LLY. Eaton Vance Management increased its stake in shares of Eli Lilly and by 72.3% in the second quarter. Eaton Vance Management now owns 5,498,527 shares of the company’s stock worth $433,009,000 after buying an additional 2,307,920 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock worth $159,402,000 after buying an additional 1,880,800 shares in the last quarter. Beutel Goodman & Co Ltd. bought a new stake in shares of Eli Lilly and during the second quarter worth $104,345,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares in the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of Eli Lilly and during the second quarter worth $86,545,000. 75.06% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Co. (NYSE:LLY) opened at 78.80 on Friday. Eli Lilly and Co. has a 12 month low of $67.88 and a 12 month high of $92.85. The stock has a market cap of $83.35 billion, a price-to-earnings ratio of 33.97 and a beta of 0.20. The firm’s 50-day moving average price is $80.07 and its 200 day moving average price is $76.54.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The company had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. During the same quarter in the prior year, the firm posted $0.90 EPS. Eli Lilly and’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Co. will post $3.59 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were issued a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a $2.04 annualized dividend and a yield of 2.59%. Eli Lilly and’s payout ratio is presently 87.93%.

A number of brokerages recently weighed in on LLY. Leerink Swann reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Sunday, June 26th. Morgan Stanley reaffirmed a “hold” rating and issued a $88.00 target price on shares of Eli Lilly and in a research note on Saturday, June 4th. BMO Capital Markets reaffirmed a “buy” rating and issued a $94.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 27th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a research note on Friday, July 29th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Eli Lilly and in a research note on Thursday, May 26th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Eli Lilly and has a consensus rating of “Buy” and an average price target of $96.85.

In other Eli Lilly and news, Director Jackson P. Tai bought 2,560 shares of Eli Lilly and stock in a transaction on Friday, August 12th. The shares were acquired at an average price of $80.42 per share, for a total transaction of $205,875.20. Following the completion of the purchase, the director now directly owns 42,110 shares in the company, valued at approximately $3,386,486.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $78.46, for a total value of $16,868,900.00. Following the completion of the sale, the insider now owns 126,808,704 shares in the company, valued at approximately $9,949,410,915.84. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).

Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.